Source comparison
Pharmacokinetics: Oral Bioavailability vs Subcutaneous Injection
MK-677 demonstrates oral bioavailability of approximately 60–70%, with peak plasma concentrations occurring 2–3 hours post-dose and an elimination half-life of 4–6 hours. Despite the relatively short half-life, the pharmacodynamic effect (elevated GH secretion
This comparison does not assign a generated winner or score.
- MK-677 demonstrates oral bioavailability of approximately 60–70%, with peak plasma concentrations occurring 2–3 hours post-dose and an elimination half-life of 4–6 hours. Despite the relatively short half-life, the pharmacodynamic effect (elevated GH secretion) persists for 24 hours due to sustained receptor occupancy and downstream signaling. Standard research doses range from 10mg to 25mg administered once daily, typically in the evening to align with natural nocturnal GH secretion patterns.
- GHRP-class peptides require subcutaneous or intramuscular injection due to rapid enzymatic degradation in the gastrointestinal tract. Bioavailability via injection approaches 100%, but the compounds are cleared within 30–60 minutes, necessitating dosing 2–3 times daily to maintain consistent GH stimulation. Ipamorelin has the shortest half-life (approximately 2 hours), while modified sequences like CJC-1295 (with DAC. Drug affinity complex) extend duration to 6–8 days through albumin binding.
- The practical implication for multi-week research protocols: MK-677 requires one daily oral administration with no refrigeration (stable at room temperature for 60+ days), while peptide vials demand reconstitution with bacteriostatic water, refrigerated storage at 2–8°C, and precise injection timing. Peptide degradation occurs rapidly above 8°C. A single temperature excursion during shipping or storage can denature the amino acid sequence entirely, rendering the compound inactive. We've found protocols using GHRP-2 require cold-chain logistics that MK-677 bypasses, reducing experimental variables related to storage consistency.